Cargando…

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index

BACKGROUND AND AIMS: Chronic hepatitis B patients in Taiwan with no or limited liver injury are not reimbursed for antiviral treatment by the Taiwan National Health Insurance (NHI). Innovative fibrosis marker, age-adjusted Fibrosis-4 Index (FIB4-AA), was implemented to evaluate the tendency of liver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ta-Wei, Huang, Chung-Feng, Yeh, Ming-Lun, Tsai, Pei-Chien, Jang, Tyng-Yuan, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745320/ https://www.ncbi.nlm.nih.gov/pubmed/33323472 http://dx.doi.org/10.1136/bmjgast-2020-000543

Ejemplares similares

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan
por: Tsai, Pei-Chien, et al.
Publicado: (2021)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis
por: Salhab, Ahmad, et al.
Publicado: (2022)

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
por: Rao, Jianhua, et al.
Publicado: (2022)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice
por: Liu, Chih-Wei, et al.
Publicado: (2020)

Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells
por: Dai, Zhen, et al.
Publicado: (2020)

Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD
por: Al-Karaghouli, Mustafa, et al.
Publicado: (2022)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
por: Mózes, Ferenc Emil, et al.
Publicado: (2022)

Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study
por: Wang, Kun, et al.
Publicado: (2019)

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
por: Ikenaga, Naoki, et al.
Publicado: (2017)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis
por: Tsai, Yu-Chi, et al.
Publicado: (2023)

The role of hepatic microenvironment in hepatic fibrosis development
por: Meng, Ying, et al.
Publicado: (2022)

Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals
por: Huang, Chung-Feng, et al.
Publicado: (2018)

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
por: Poynard, Thierry, et al.
Publicado: (2015)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya
por: Mburu, Anne Njeri, et al.
Publicado: (2023)

Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study
por: Park, Jung Gil, et al.
Publicado: (2020)

The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C
por: Lee, Jia-Jung, et al.
Publicado: (2020)

Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients
por: Batsaikhan, Batbold, et al.
Publicado: (2022)

Hepatic fibrosis and factors associated with liver stiffness in HIV mono-infected individuals
por: Sulyok, Mihály, et al.
Publicado: (2017)

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
por: Stokman, Geurt, et al.
Publicado: (2020)

Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis
por: Wu, Chia-Che, et al.
Publicado: (2018)

Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection
por: Jin, Young-Joo, et al.
Publicado: (2014)

Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update
por: Erman, Aysegul, et al.
Publicado: (2019)

Close association of PFASs exposure with hepatic fibrosis than steatosis: evidences from NHANES 2017–2018
por: Cheng, Wenli, et al.
Publicado: (2023)

Evaluation of liver fibrosis in patients with Wilson’s disease
por: Przybyłkowski, Adam, et al.
Publicado: (2020)

Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study
por: Nah, Eun-Hee, et al.
Publicado: (2021)

Does bariatric surgery influence plasma levels of fetuin-A and leukocyte cell-derived chemotaxin-2 in patients with type 2 diabetes mellitus?
por: Huang, Hsien-Hao, et al.
Publicado: (2018)

Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study
por: Coelho, Juliana Moraes, et al.
Publicado: (2020)

Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? protocol for a feasibility randomised controlled trial
por: Subhani, Mohsan, et al.
Publicado: (2021)

A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice
por: Zheng, Shumei, et al.
Publicado: (2022)

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
por: Lin, Ching-Chih, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cs5tccm3ps155jee4hvviqjne4